Featured Research

from universities, journals, and other organizations

Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma

Date:
February 10, 2014
Source:
European Organisation for Research and Treatment of Cancer
Summary:
An analysis has confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.

An EORTC analysis appearing in Annals of Oncology confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.

Soft tissue sarcomas are a heterogeneous and relatively rare tumor with an estimated incidence of four per 100,000 people per year in Europe. The prognosis for patients with this disease is favorable if they are diagnosed at an early stage and if all of the tumor can be completely removed surgically. Unfortunately, half of all patients develop distant metastases, and the median overall survival for advanced patients is only about twelve months.

Prof. Dr. Bernd Kasper of the Sarcoma Unit of the Interdisciplinary Tumor Center at the Mannheim University Medical Center in Germany and lead author of this analysis says, "One approach to treat patients with advanced stage soft tissue sarcoma is to target angiogenesis, and pazopanib is a recently approved orally available angiogenesis inhibitor. We analyzed pooled data from two prospective EORTC trials, the phase II trial in which 118 patients and the phase III PALETTE trial in which 226 patients were treated with pazopanib, to characterize long-term survivors and responders."

At a median follow-up of 2.3 years, the investigators found that 36 % of the patients had a progression-free survival of six months or longer, defined as long-term responders, and 34 % survived 18 months or longer, defined as long-term survivors. Furthermore, 3.5 % of patients remained progression free under pazopanib for more than two years. Median time on pazopanib in these patients was 2.4 years with longest duration of 3.7 years. In summary, good performance status, low / intermediate grade of the primary tumor and a normal hemoglobin level at baseline were advantageous for long-term outcome.


Story Source:

The above story is based on materials provided by European Organisation for Research and Treatment of Cancer. The original article was written by John Bean. Note: Materials may be edited for content and length.


Journal Reference:

  1. B. Kasper, S. Sleijfer, S. Litiere, S. Marreaud, J. Verweij, R. A. Hodge, S. Bauer, J. M. Kerst, W. T. A. van der Graaf. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Annals of Oncology, 2014; DOI: 10.1093/annonc/mdt586

Cite This Page:

European Organisation for Research and Treatment of Cancer. "Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma." ScienceDaily. ScienceDaily, 10 February 2014. <www.sciencedaily.com/releases/2014/02/140210101957.htm>.
European Organisation for Research and Treatment of Cancer. (2014, February 10). Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2014/02/140210101957.htm
European Organisation for Research and Treatment of Cancer. "Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma." ScienceDaily. www.sciencedaily.com/releases/2014/02/140210101957.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins